Dashboard
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 12.73% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Flat results in Jun 25
3
Risky -
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
HKD 4,277 Million ()
NA (Loss Making)
NA
0.00%
-0.89
-35.30%
5.48
Revenue and Profits:
Net Sales:
19 Million
(Quarterly Results - May 2023)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.18%
0%
13.18%
6 Months
-31.0%
0%
-31.0%
1 Year
20.8%
0%
20.8%
2 Years
5.61%
0%
5.61%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Laekna, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
12.73%
EBIT to Interest (avg)
-132.76
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.54
EV to EBIT
-19.06
EV to EBITDA
-19.40
EV to Capital Employed
67.18
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-352.57%
ROE (Latest)
-35.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - May'23 - YoY
May'23
May'22
Change(%)
Net Sales
19.30
0.00
Operating Profit (PBDIT) excl Other Income
-0.20
-0.10
-100.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.20
-0.10
-100.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended May 2023 is 0.00% vs 0.00% in May 2022
Consolidated Net Profit
YoY Growth in quarter ended May 2023 is -100.00% vs 0.00% in May 2022
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-318.40
-422.30
24.60%
Interest
1.90
1.60
18.75%
Exceptional Items
-93.00
-474.60
80.40%
Consolidate Net Profit
-407.50
-908.90
55.17%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 55.17% vs -0.69% in Dec 2022
About Laekna, Inc. 
Laekna, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






